Locust Walk

Menu

Asia Transactions Expertise

Bridging Global Innovation Through Local Insight in China and Japan

Locust Walk enables biopharma companies to achieve transformative deals across the Pacific by combining deep regional knowledge with seasoned global execution. Our on-the-ground teams in China and Japan deliver strategic guidance, market intelligence, and cultural fluency to help clients navigate the complexities of cross-border transactions.

Why Asia Matters

Asia is a growing engine for biopharma innovation, with China and Japan leading in asset development.

  • Chinese-originated assets represent a significant share of global licensing deals.

  • Japanese pharma is valued for its scientific rigor and global appetite for deals.

  • Many companies face barriers in Asia due to language, governance, and information gaps.

Locust Walk is uniquely positioned to bridge market access gaps with local teams and deep cross-border experience.

China Capabilities

Locust Walk’s China team provides end-to-end support for Chinese companies seeking to partner their innovation with the west via strategic partnerships or newcos.

What Sets Us Apart:

Holistic Market Intelligence

We go beyond public data—combining local sentiment, ecosystem insights, and informal indicators to assess opportunities.

Embedded Local Team

Our China team operates in-market, backed by global processes to ensure deal quality and consistency.

Unique Dealflow Expertise

We navigate six distinct company types and understand the regulatory, policy, and access dynamics others often miss.

Proven Deal Process

Our structured approach from target identification through deal close reduces friction and improves outcomes.

Japan Capabilities

Locust Walk’s Japan practice is led by seasoned experts with deep C-level relationships across the Japanese biopharma ecosystem, spanning large pharmaceutical companies, biotechs, and investors.

What Sets Us Apart:

Deep-Rooted Relationships

Our team has longstanding ties across Japanese pharma, enabling privileged access and trusted dialogue with key decision-makers.

Local Insight, Global Execution

We combine cultural fluency and local regulatory knowledge with global dealmaking expertise to deliver effective cross-border outcomes.

Strategic Navigation of the Japanese Landscape

We help clients overcome barriers posed by language, governance, and market nuance, while capitalizing on Japan’s scientific rigor and global partnership appetite.

Track Record Across Deal Types

From licensing and M&A to new company creation and spinouts, our Japan team has successfully executed diverse transactions aligned with client strategy.

Our China Capabilities

Locust Walk’s China team provides end-to-end support for companies seeking to source innovation from or expand partnerships into China.

What Sets Us Apart:

Holistic Market Intelligence

We go beyond public data—combining local sentiment, ecosystem insights, and informal indicators to assess opportunities.

Embedded Local Team

Our China team operates in-market, backed by global processes to ensure deal quality and consistency.

Unique Dealflow Expertise

We navigate six distinct company types and understand the regulatory, policy, and access dynamics others often miss.

Proven Deal Process

Our two-phase approach, from target ID to deal close, reduces friction and improves outcomes.

Our Japan Capabilities

Locust Walk’s Japan practice is led by senior experts with deep relationships across the Japanese biopharma ecosystem, spanning large pharmaceutical companies, biotechs, and investors.

What Sets Us Apart:

Deep-Rooted Relationships

Our team has longstanding ties across Japanese pharma, enabling privileged access and trusted dialogue with key decision-makers.

Local Insight, Global Execution

We combine cultural fluency and local regulatory knowledge with global dealmaking expertise to deliver effective cross-border outcomes.

Strategic Navigation of the Japanese Landscape

We help clients overcome barriers posed by language, governance, and market nuance, while capitalizing on Japan’s scientific rigor, strong regulatory infrastructure, and global partnership appetite.

Track Record Across Deal Types

From licensing and M&A to new company creation and spinouts, our Japan team has successfully executed diverse transactions aligned with client strategy.

Meet Our Asia Leadership

Hiroshi Yamamoto

Managing Director, Japan
Read More
Eric Liu

Eric Liu

Managing Director, China
Read More

Peter Chiu

Senior Advisor, Taiwan
Read More

Asia-Focused Insights

2025 Q2 Report: Global Trends in Biopharma Transactions

DOWNLOAD

Biotalk Episode 28: 2025 Q2 Report: Global Trends in Biopharma Transactions

Episode 29: Asia’s 2025 Q2 Report: Global Trends in Biopharma Transactions

LISTEN

China Supermarket

DOWNLOAD

Start the Conversation

Looking to explore a transaction in China or Japan? Our team is ready to help.
To schedule a meeting, contact us at asia@locustwalk.com.

Contact Us Today
Scroll to Top